Synopsis: Goldman Sachs and Citigroup maintain “Sell” ratings on Dr. Reddy’s Laboratories Limited, citing weak growth outlook, limited pipeline opportunities, earnings pressure, and valuation concerns, indicating nearly 20% downside risk.
This Large-Cap Pharma Stock, engaged in manufacturing and marketing generic medicines, biosimilars, and APIs, serving global healthcare markets with affordable pharmaceutical solutions, in focus after Goldman Sachs and Citi gave a Sell target of Rs. 1,075 and 1,070, which has a downside potential of up to 19.82 percent.
With a market capitalization of Rs. 1,11,383.94 crore, the shares of Dr Reddy’s Laboratories Limited were currently trading at Rs. 1,334.55 per equity share, rising nearly 1.42 percent from its previous day’s close price of Rs. 1,315.85.
What is the News?
Goldman Sachs, a prominent brokerage firm, has recommended a “Sell” call on Dr Reddy’s Laboratories Limited with a target price of Rs. 1,075 per share, indicating a downside potential of 19.45 percent from its current price of Rs. 1,334.55 per share.
Goldman Sachs downgraded Dr. Reddy’s Laboratories as growth expectations have weakened. The generic Ozempic opportunity is now seen as smaller and short-lived, limiting upside. At the same time, the base business continues to face price erosion, pressuring margins. The company also lacks strong near-term pipeline drivers.
As a result, EPS estimates have been cut by 8–26 percent for FY26–FY28, indicating weaker future earnings. Despite this, the stock is trading at around 19x P/E, which looks expensive relative to its fundamentals. With lower earnings visibility and high valuation, Goldman Sachs sees downside risk, leading to a more cautious (Sell) view on the stock.
Likewise, Citi, a prominent brokerage firm, has recommended a “Sell” call on Dr Reddys Laboratories Limited with a target price of Rs. 1,070 per share, indicating an downside potential of 19.82 percent from its current price.
Citigroup maintains a Sell on Dr. Reddy’s Laboratories, as it believes recent optimism is overdone. The stock’s ~9 percent rise on hopes of generic Semaglutide approval may not sustain, since even with approval, the opportunity is limited due to competition.
Citi estimates revenues of only ~US$80-100 million in FY27 and ~US$50 million by FY28, indicating modest contribution. Additionally, earnings will normalize after the Revlimid boost fades, reducing profitability. Street estimates also appear too high, with Citi projecting EPS 20-23 percent below consensus. Overall, weaker earnings outlook and limited upside justify the lower target and negative stance.
Revenue Segment (Q3 FY26):
Dr. Reddy’s Laboratories Limited reported Q3 FY26 revenue of around Rs. 8,727 crore, largely fueled by its Global Generics business. This segment contributed about 91 percent (Rs. 7,911 crore), maintaining steady growth, while the PSAI segment accounted for 9 percent (Rs. 802 crore). Other segments had a negligible impact.
On the regional front, North America remained the biggest market at Rs. 2,964 crore, though it saw a slight decline. In contrast, Europe (Rs. 1,448 crore), India (Rs. 1,603 crore), and Emerging Markets (Rs. 1,896 crore) delivered solid growth. Overall performance was broad-based across geographies, supported by favorable currency movements, although partially offset by product-specific headwinds in the U.S. market.
Company Overview:
Dr. Reddy’s Laboratories Limited is a global pharmaceutical firm based in Hyderabad. Established in 1984 by Kallam Anji Reddy, the company has evolved into one of India’s largest drug manufacturers and a major international provider of generic medicines, biosimilars, and active pharmaceutical ingredients (APIs). With operations spanning more than 70 countries, it delivers healthcare solutions to hundreds of millions of patients around the world.
Recent Quarter Results:
Coming into financial highlights, Dr. Reddy’s Laboratories Limited’s revenue has increased from Rs. 8,381 crore in Q3 FY25 to Rs. 8,753 crore in Q3 FY26, which has grown by 4.44 percent. The net profit has decreased by 15.24 percent from Rs. 1,404 crore in Q3 FY25 to Rs. 1,190 crore in Q3 FY26.
Dr. Reddy’s Laboratories Limited’s revenue and net profit have grown at a CAGR of 13.26 percent and 23.09 percent, respectively, over the last five years.
In terms of return ratios, the company’s ROCE and ROE stand at 22.7 percent and 18.0 percent, respectively. Dr. Reddy’s Laboratories Limited has an earnings per share (EPS) of Rs. 66.7, and its debt-to-equity ratio is 0.16x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Dr. Reddy’s: Will the Pharma Company’s Share Soon Be Trading at a 20% Discount? appeared first on Trade Brains.